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Background: The mitogen-activated protein kinases (MAPK) and the phosphatidylinositol-3-kinase (PI3K)/mammalian
target of rapamycin (mTOR) pathways are intertwined on various levels and simultaneous inhibition reduces tumorsize
and prolonges survival synergistically. Furthermore, inhibiting these pathways radiosensitized cancer cells in
various studies. To assess, if phenotypic changes after perturbations of this signaling network depend on the
genetic background, we integrated a time series of the signaling data with phenotypic data after simultaneous
MAPK/ERK kinase (MEK) and PI3K/mTOR inhibition and ionizing radiation (IR).
Methods: The MEK inhibitor AZD6244 and the dual PI3K/mTOR inhibitor NVP-BEZ235 were tested in glioblastoma
and lung carcinoma cells, which differ in their mutational status in the MAPK and the PI3K/mTOR pathways.
Effects of AZD6244 and NVP-BEZ235 on the proliferation were assessed using an ATP assay. Drug treatment and
IR effects on the signaling network were analyzed in a time-dependent manner along with measurements of
phenotypic changes in the colony forming ability, apoptosis, autophagy or cell cycle.
Results: Both inhibitors reduced the tumor cell proliferation in a dose-dependent manner, with NVP-BEZ235
revealing the higher anti-proliferative potential. Our Western blot data indicated that AZD6244 and NVP-BEZ235
perturbed the MAPK and PI3K/mTOR signaling cascades, respectively. Additionally, we confirmed crosstalks and
feedback loops in the pathways. As shown by colony forming assay, the AZD6244 moderately radiosensitized
cancer cells, whereas NVP-BEZ235 caused a stronger radiosensitization. Combining both drugs did not enhance
the NVP-BEZ235-mediated radiosensitization. Both inhibitors caused a cell cycle arrest in the G1-phase, whereas
concomitant IR and treatment with the inhibitors resulted in cell line- and drug-specific cell cycle alterations.
Furthermore, combining both inhibitors synergistically enhanced a G1-phase arrest in sham-irradiated
glioblastoma cells and induced apoptosis and autophagy in both cell lines.
Conclusion: Perturbations of the MEK and the PI3K pathway radiosensitized tumor cells of different origins and
the combination of AZD6244 and NVP-BEZ235 yielded cytostatic effects in several tumor entities. However, this is
the first study assessing, if the combination of both drugs also results in synergistic effects in terms of
radiosensitivity. Our study demonstrates that simultaneous treatment with both pathway inhibitors does not lead
to synergistic radiosensitization but causes cell line-specific effects.
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Table 1 Mutations of known cancer genes in the glioblastoma
SNB19 and the lung carcinoma A549 cell lines [30]
Cell line Gene Variant Effect
SNB19 CDKN2A Hom c.1_471 del 471, p.? LOM
PTEN Hom c.723_724insTT p.E242fsX15 LOM
TP53 Hom c.818G > A, p.R273H LOM
A549 CDKN2A Hom c.1_471 del 471, p.? LOM
KRAS Hom c.34G > A, p.G12S LOM
STK11 Hom c.109C > T, p.Q37X LOM
Abbreviations: Hom homozygous, del deletion, LOM likely oncogenic mutation
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Standard therapy for solid tumors traditionally consists of
different approaches, including surgical resection, hormone
therapy, systemic chemotherapy and radiotherapy. How-
ever, within the last years combining the traditional
approaches with molecular targeted therapies, using
monoclonal antibodies and small molecule inhibitors,
has become more and more important [71]. Prime targets
for this strategy for tumor control are oncogenic signaling
cascades, such as the januskinase/signal transducers and ac-
tivators of transcription, the tumor necrosis factor signaling
or the mitogen-activated protein kinases (MAPK) pathway.
Especially the MAPK signaling pathway has been shown to
stimulate proliferation, cell growth, survival and resistance
to chemotherapeutics and ionizing radiation IR [7, 10, 12].
In particular the novel ATP non-competitive MEK inhibitor
AZD6244 (generic names: Selumetinib, ARRY-142886)
demonstrated high specificity and anti-proliferative activity
in in vitro and in vivo models [69]. Various research groups
demonstrated, that apart from the cytostatic effects, AZD
6244 also sensitized human tumor cell lines of different ori-
gins to IR, underlining the potential of the MAPK pathway
as a target for radiosensitization [9, 10, 62].
Another important oncogenic signaling cascade for a
molecular targeted therapy is the phosphatidylinositol
3-kinase (PI3K)/mammalian target of rapamycin (mTOR)
pathway, which is also related to proliferation and therapy
resistance and which also has been validated as a target for
radiosensitizing approaches in various in vitro and in vivo
studies [8, 19, 32, 40, 58]. Especially the dual PI3K/mTOR
inhibitor NVP-BEZ235 revealed a promising radiosensitiz-
ing potential in several experiments [20, 21, 37, 38, 49].
Although, first promising results were obtained for
signaling cascade inhibitors in cancers depending on
mutations of a single signaling pathway, only limited
treatment success was observed, when multiple signal-
ing cascades were deregulated [15, 16, 27], indicating a
dependency on the individual mutational background.
One possible reason for this limited therapy success is the
compensatory up regulation of (other) pathways by feed-
back loops and/or crosstalks after drug treatment. Such
compensatory activation has been shown for a number of
cell lines of different tumor entities pointing to its involve-
ment in treatment resistance [34, 35, 42]. Apart from this
cell specific a priori resistance to various drugs, the perturb-
ation of a signaling pathway can also result in an acquired
drug resistance of initially responsive tumor cells, which
ultimately leads to treatment failure [31]. One approach to
avoid this resistance by the induction of complementary
signaling after drug treatment is to combine inhibitors of
different pathways in order to achieve synergistic effects by
inhibiting the complementary signaling cascades. In fact, it
was proven in several in vitro and in vivo studies, that sim-
ultaneous perturbation of the MAPK and the PI3K/mTORpathways resulted in enhanced effects compared to single
pathway inhibition [5, 25, 53, 66].
Especially the MEK inhibitor AZD6244 and the dual
PI3K/mTOR inhibitor NVP-BEZ235 demonstrated syner-
gistic effects in several in vitro studies investigating vari-
ous tumor entities [24, 26, 53, 56, 59]. Furthermore, the
promising in vitro effects of the combined treatment with
AZD6244 and NVP-BEZ235 were already validated in sev-
eral xenografts in vivo studies with cells of different tumor
entities, showing significant synergistic effects including
increased tumor shrinkage and prolonged median survival
after combined treatment [17, 47, 52, 63].
Although there are several publications, validating
the synergistic effects of simultaneous treatment with
AZD6244 and NVP-BEZ235, to our knowledge there
is no study available evaluating if these synergistic
effects are enhanced, when the drugs are combined
with IR. To assess the effects of simultaneous MEK
and PI3K/mTOR inhibition on the MAPK and PI3K/
mTOR signaling cascades and to integrate these data
with the phenotypic data of the radiation response
after simultaneous MEK and PI3K/mTOR inhibition,
we treated glioblastoma SNB19 and lung carcinoma
A549 cells with AZD6244 and NVP-BEZ235 alone and
in combination. The two cell lines differ in their muta-
tional status, as shown in Table 1, which summarizes
mutations of known cancer genes in the two cell lines
[30]. As illustrated in Table 1, both cell lines have a
common mutation in CDK2NA, which codes for the
tumor suppressor protein p16. However, the two cell
lines differ in their mutational status regarding the
oncogenic MAPK and PI3K/mTOR pathways. SNB19
cells are not expressing functional phosphatase and
tensin homologue (PTEN), which is a negative regulator
of the PI3K/mTOR signaling cascade [70]. A549 lung car-
cinoma cells in contrast do not have any known mutations
in the PI3K/mTOR pathway, but a mutation in the Kirsten
rat sarcoma viral oncogene homolog (KRAS) gene, which
occurs in about 30 % of non small cell lung cancers [6].
These mutations result in a constitutive active form of the
protein [1], ultimately leading to activation of the MAPK
signaling cascade.
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BEZ235 on the cellular proliferation rates and the
expression levels of several key proteins of the MAPK
(Raf-1, p-MEK1/2, MEK2, p-Erk1/2 and Erk2) and
PI3K/mTOR signaling cascades (PI3K p110, PI3K p85,
PTEN, p-Akt, Akt, p-mTOR, mTOR, p-S6, S6 and p-4E-
BP1), we assessed the colony forming abilities, the cell
cycle phase distributions, the expression levels of cell cycle
related proteins (CDK1, CDK4 and p-Rb), the incidence of
apoptosis markers (hypodiploid cells and poly (ADP-Ri-
bose) polymerase (PARP) expression levels and cleavage)
and the expression levels of autophagy related proteins
(LC3-I and LC3-II) dependent on drug treatment and IR.
Methods
Cell culture and drug treatment
The human lung cancer cell line A549 and the human
glioblastoma cell line SNB19 were obtained from the “Cell
Line Services” company (Heidelberg, Germany) and rou-
tinely cultured under standard conditions (37 °C, 5 % CO2)
in Dulbecco’s modified Eagle’s medium supplemented with
10 % FBS, 1 % glutamine and 1 % Penicillin-Streptomycin.
For the proliferation assays cells were treated for 24 h with
the indicated concentrations of AZD6244 (Selleckchem,
Houston, TX, USA) and NVP-BEZ235 (Novartis Institutes
for Biomedical Research, Basel, Switzerland) before meas-
urement of the ATP content. For the other experiments of
this study cells were treated 16 or 1 h prior to IR with 500
nM AZD6244 or 50 nM NVP-BEZ235, respectively. Drugs
were freshly diluted from frozen aliquots stored at −20 °C.
Cells treated in parallel with dimethylsulfoxide (DMSO)
served as controls.
Cell viability assay
The proliferation rate was analyzed with the CellTiter-Glo
Luminescent Cell Viability Assay (Promega, Madison, WI,
USA) according to the manufacturer’s instructions. Serial
dilutions of AZD6244 (31.25–4000 nM) or NVP-BEZ235
(3.125-400 nM) were added to exponentially growing cells
and the ATP levels were determined 24 h afterwards.
Furthermore, experiments with serial dilutions of AZD6244
(31.25–4000 nM) in the presence of 50 nM NVP-BEZ235
and NVP-BEZ235 (3.125–400 nM) in the presence of 500
nM AZD6244 were performed. Experiments were done in
triplicates and the mean ATP content data derived from
two independent experiments were normalized against
DMSO-treated controls to generate dose–response curves.
Further analysis of the data was basically performed as
described previously [38].
X-ray IR
IR was performed at room temperature using a 6 MV linear
accelerator (Siemens, Concord, USA) at a dose rate of2 Gy/min. After IR, cells were cultured in standard condi-
tions for the indicated time until harvest.
Western blot
The preparation of whole cell lysates, separation according
the protein size using Western blotting techniques and the
detection of protein levels using protein-specific primary
and species-specific peroxidase-labeled secondary anti-
bodies were performed according standard protocols as
described previously [68]. The antibodies used in this study
are specified in Additional file 1. Protein expression levels
were quantified using ImageJ (NIH, Bethesda, MD, USA),
normalized to β-actin levels and the relative protein
expressions of the shown representative biological replicate
are denoted by numbers below the corresponding blot (if
changes between treatments were observed). For each
Western blot experiment three independent biological rep-
licates were performed.
Colony forming assay
Colony forming assays were performed and data were
analyzed with the linear quadratic model as described
elsewhere [22]. Briefly, cells were treated with 500 nM
AZD6244 and/or 50 nM NVP-BEZ235 16 h or 1 h
prior to IR, respectively. Twenty-four hours after IR
with graded single doses up to 8 Gy the cells were
detached and seeded into 6 well plates containing drug
free medium. Cells were then cultivated under stand-
ard conditions for two weeks. Colonies were stained
with 0.6 % crystal violet and colonies containing more
than 50 cells, were scored as survivors. Experiments
were done in triplicate and each experiment was re-
peated at least four times.
Measurement of cell cycle phase distribution and
hypodiploid cells
Cell cycle phase distributions and proportion of hypodip-
loid cells were assessed as described elsewhere [55]. Briefly,
samples were fixed 30 min, 24 and 48 h after IR by adding
ice cold ethanol. After permeabilization and treatment with
RNase A cells were stained with propidium iodide (PI) and
at least 20,000 cells were assessed for their DNA content,
using a flow cytometer FACSCanto II (Becton Dickinson,
San Jose, CA, USA). For cell cycle analysis cell conglomer-
ates and hypodiploid cells were excluded and deconvolu-
tion of DNA histograms was performed using the ModFit
LT (Verity Software House, Topsham, ME, USA) software.
Cells showing less than 80 % of the fluorescence signal of
average G1-phase cells were considered to be hypodiploid.
Software and statistics
Data are represented as means ± standard deviation (SD)
of at least three independent experiments. Unpaired two-
sided t-tests were performed and P values <0.05 were
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comparisons the Holm-Bonferroni method of alpha error
correction was applied. Statistical comparison of colony
forming assays was done using the statistical software
RStudio 0.96.331 (Free Software Foundation, Boston, MA,
USA) along with the package CFAssay (H. Braselmann,
Helmholtz Zentrum German Research Center for En-
vironmental Health, Munich, Germany). For statistical
comparisons of the cell cycle phase distribution data we
tested each cell cycle phase (G1-, S- or G2/M-phase)
between the different treatment groups (Control, AZD
6244, NVP-BEZ235, and AZD6244 + NVP-BEZ235).
Statistical significant differences in at least one of the cell
cycle phases between the different treatment groups are
indicated in the figure. For reasons of clarity we omitted
comparisons between unirradiated and irradiated samples.
Further software used in this study was Flowing Software
(P. Terho, Turku Centre for Biotechnology, Turku,
Finland), ImageJ (NIH, Bethesda, MD, USA) and Origin
8.5 (Microcal, Northampton, MA, USA).
Results
AZD6244 and NVP-BEZ235 decrease cell proliferation and
perturb oncogenic signaling cascades
To assess the effects of AZD6244 or NVP-BEZ235 on glio-
blastoma SNB19 and lung carcinoma A549 cells, we treated
both cell lines with serial dilutions of the inhibitors within a
concentration range of 31.25-4000 nM for AZD6244 and
3.125-400 nM for NVP-BEZ235 and quantified the cell
viability by the CellTiter-Glo Luminescent Cell Viability
Assay. ATP content in drug-treated samples was normal-
ized against DMSO treated controls and plotted against the
drug concentration. To evaluate the effect of combining
both inhibitors, further experiments with serial dilutions of
AZD6244 in the presence of 50 nM NVP-BEZ235 or
NVP-BEZ235 in the presence of 500 nM AZD6244 were
performed. As evident from Fig. 1 an incubation with
increasing concentrations of the MEK inhibitor AZD6244
decreased cell proliferation to about 85 % in SNB19 and
to about 75 % in A549 cells. An incubation with serial
dilutions of the dual PI3K/mTOR inhibitor NVP-BEZ235
also decreased the proliferation rates in both cell lines. In
the SNB19 cell line NVP-BEZ235 concentrations higher
than 12.5 nM caused a decrease of the relative ATP
content to a minimum of approximately 70 %, which was
achieved by an incubation with 50 nM or higher concen-
trations of NVP-BEZ235. Incubation of A549 cells with
NVP-BEZ235 already caused a decrease of the relative
ATP level at low nanomolar concentrations. A minimum
relative ATP level of about 50 % was achieved when the
lung carcinoma cells were treated with NVP-BEZ235 con-
centrations of 50 nM or higher.
To address the question, if there are synergistic effects
on the proliferation rate after combing AZD6244 andNVP-BEZ235, we used a combination of both inhibitors
with serial dilutions of AZD6244 (31.25–4000 nM) and 50
nM of NVP-BEZ235 or of NVP-BEZ235 (3.125-400 nM)
with 500 nM of AZD6244. We chose a concentration of
50 nM for NVP-BEZ235 and 500 nM for AZD6244 since
these concentrations are in the range of previously pub-
lished data regarding radiosensitizing effects of the PI3K/
mTOR and MEK inhibitor [9, 20, 21, 37, 51, 62], which
we wanted to investigate in combination in this study. As
demonstrated in Fig. 1, an incubation of SNB19 cells with
increasing AZD6244 concentrations along with 50 nM of
NVP-BEZ235 resulted in a relative ATP level of about
70 %, which was also achieved by incubation with 50 nM
NVP-BEZ235 alone. In A549 cells incubation with 31.25-
500 nM AZD6244 along with 50 nM NVP-BEZ235 also
revealed no synergistic effects. However, when the cells
were treated with AZD6244 concentrations higher than
1000 nM in combination with 50 nM NVP-BEZ235 a de-
crease of the relative ATP level was observed. Incubation
of SNB19 cells with increasing NVP-BEZ235 concentra-
tions in combination with 500 nM AZD6244 revealed no
further effects on the relative ATP content then treatment
with the dual PI3K/mTOR inhibitor alone. The treatment
of A549 cells with increasing NVP-BEZ235 concentrations
along with 500 nM AZD6244 resulted in a decreased
relative ATP level at low nanomolar NVP-BEZ235 con-
centrations compared to treatment with NVP-BEZ235
solely. However, with NVP-BEZ235 concentrations
higher than 10 nM this synergistic effect vanished. For
subsequent experiments we used drug concentrations
of 500 nM for AZD6244 and 50 nM for NVP-BEZ235,
which are in line with previously published experiments
[10, 38, 43, 69].
To elucidate the molecular changes for the observed
anti-proliferative effects, we assessed the expression and
phosphorylation levels of several proteins of the MAPK
and the PI3K/mTOR pathway after drug treatment and IR
in a time-dependent manner. As shown in Fig. 2a the
incubation with the MEK inhibitor AZD6244 resulted in
an increased phosphorylation of MEK1/2 and a decreased
phosphorylation of Erk1/2 in SNB19 and A549 cells
30 min after IR. These increased p-MEK1/2 and decreased
p-Erk1/2 levels were also observed 24 and 48 h after IR in
both cell lines (Fig. 2a). The treatment with the dual
PI3K/mTOR inhibitor NVP-BEZ235 had only minor
effects on the proteins of the MAPK pathway 30 min after
IR. However, as demonstrated in Fig. 2b, incubation with
NVP-BEZ235 reduced the expression levels of Raf-1 in
both cell lines 24 and 48 h after IR.
As illustrated in Fig. 2b, the tumor suppressor protein
PTEN was only detectable in PTEN wild type A549 cells,
whereas it was absent in the SNB19 cell line. This corre-
lated with the expression of p-Akt, which is negatively
regulated by PTEN and which was activated in SNB19
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Fig. 1 Proliferation assays of SNB19 and A549 after treatment AZD6244 and/or NVP-BEZ235. Effect of 24 h exposure to serial dilutions of AZD6244
(blue squares), AZD6244 with 50 nM NVP-BEZ235 (red triangels), NVP-BEZ235 (green circles) or NVPBEZ235 with 500 nM AZD6244 (black diamonds) on
the ATP level in SNB19 or A549 cells, as measured by a standard luciferase assay. The diagram represents the means of two independent experiments,
each performed in triplicates, normalized against DMSO-treated controls. Dose–response curves (illustrated in the corresponding color) were generated
using the standard four parameter logistic models and error bars indicate SD values
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sion of several other proteins of the PI3K/mTOR signaling
cascade, incubation with the MEK inhibitor AZD6244 had
no effect on the proteins of the PI3K/mTOR pathway. In
contrast, the treatment with NVP-BEZ235 resulted in
decreased p-Akt levels 30 min after IR in SNB19 cells
(Fig. 2b). Interestingly, simultaneous incubation of SNB19
cells with both inhibitors resulted in a diminished de-
crease of p-Akt compared to the treatment with NVP-
BEZ235 alone. However, 24 and 48 h after IR the initially
decreased p-Akt levels in NVP-BEZ235-treated SNB19
cells recovered to a higher phosphorylation level of Aktthan in the control samples (Fig. 2b). This effect was inde-
pendent of IR and co-incubation with AZD6244.
Apart from its effect on Akt phosphorylation, incubation
of SNB19 cells with NVP-BEZ235 caused a dephosphory-
lation of 4E-BP1 and a slight dephosphorylation of S6
30 min after IR (Fig. 2b). This NVP-BEZ235 induced
dephosphorylation of S6 was fortified 24 and 48 h after IR,
thus p-S6 could hardly be detected at these time points.
The reduced levels of p-4E-BP1 after incubation with
NVP-BEZ235 were measured also 24 and 48 h after IR
(Fig. 2b). The inhibition of the PI3K/mTOR pathway by
NVP-BEZ235, as indicated by decreased S6 and 4E-BP1
A)
B)
Fig. 2 Expression levels of selected proteins of the MAPK/Erk and the PI3K/mTOR pathways in SNB19 and A549 cells. Representative Western blot
analysis of expression levels of selected proteins of the MAPK a and the PI3K/mTOR pathway b in SNB19 and A549 cells. Cells were treated with
AZD6244 and/or NVP-BEZ235 before IR with 8 Gy and whole cell lysates were prepared 30 min, 24 h and 48 h after IR. Protein bands were
normalized to the β-actin intensity and changes in protein expression are denoted by numbers if applicable. Since the utilized antibody detected
p-Erk1 and p-Erk2 the numbers below the blot correspond to the expression levels of total p-Erk1/2
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incubation with AZD6244. The A549 cell line showed
qualitatively similar results, except for Akt phosphoryl-
ation, which was not detectable in this cell line. Other
proteins of the PI3K/mTOR pathway (PI3K p110, PI3K
p85, p-mTOR and mTOR) were also analyzed, but did not
reveal any noteworthy changes in protein expression or
phosphorylation (data not shown).
A putative signaling diagram, derived from our Western
blot and literature data, illustrating the AZD6244 and
NVP-BEZ235 induced perturbations in the MAPK and
the PI3K/mTOR signaling cascades is depicted in Fig. 3.
Inhibition of the MAPK signaling pathway with AZD6244
caused reduced phosphorylation of Erk, but increased the
phosphorylation of MEK pointing towards a feedback loop
from Erk to the top of the signaling cascade, as depicted
in the diagram. Likewise, the perturbation of the PI3K/
mTOR pathway with NVP-BEZ235 also caused the induc-
tion of a feedback loop, as indicated by the increased
phosphorylation of Akt in SNB19 cells. Furthermore, a
crosstalk between the PI3K/mTOR and the MAPK path-
way was confirmed by Western blotting (Fig. 3). In orderto further analyze the phenotypic effects of inhibiting the
MAPK and PI3K/mTOR signaling cascades, especially in
the light of the radiation response, we measured the
colony forming abilities, cell cycle aberrations and the
induction of apoptosis and autophagy after treatment with
AZD6244 and/or NVP-BEZ235 in irradiated and sham-
irradiated cells.
Effects of AZD6244 and NVP-BEZ235 on the
radiosensitivity
To assess the effects of perturbations in the oncogenic
MAPK and PI3K/mTOR signaling cascades on the
radiosensitivity, we treated SNB19 and A549 cells with
AZD6244, NVP-BEZ235 or a combination of both in-
hibitors before IR with single doses up to 8 Gy. Figure 4
shows the mean normalized clonogenic survival responses
of at least four independent experiments plotted against
the radiation dose along with the best fits of the linear
quadratic model to the data. The mean plating efficiencies
and radiosensitivity parameters derived from the best fits
of the linear quadratic models for both cell lines are sum-
marized in Additional file 2.
Fig. 3 Putative interactions and feedback loops in the MAPK and PI3K/mTOR signaling cascades. Putative signaling diagram of the MAPK and PI3K/
mTOR pathways derived from the Western blot analysis shown Fig. 2 and literature data specified in the text. Treatment with the allosteric MEK inhibitor
AZD6244 causes desphosphorylation of Erk resulting in phenotypic changes (e.g. changes in the proliferation rate, cell cycle phase distribution and
radiosensitivity). However, simultaneously the MAPK pathway is activated through a feedback loop from Erk to the upper part of the signaling cascade
resulting in hyperphosphorylation of MEK. Inhibiting the PI3K/mTOR pathway with NVP-BEZ235 caused a dephosphorylation of the transcription and
translation regulators S6 and 4E-BP1 also inducing the aforementioned phenotypic changes. However, also for the PI3K/mTOR pathway we observed a
feedback loop, as indicated by increased Akt phosphorylation after PI3K and mTOR inhibition in SNB19 cells. Furthermore, we validated a crosstalk
between the two signaling cascades since treatment with the dual PI3K/mTOR inhibitor also resulted in decreased Raf-1 expression levels. Stimulation is
indicated by black normal arrows, whereas inhibition is indicated by red blunt arrows
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caused a slight decrease in both, the surviving frac-
tion at 2 Gy (SF2) and the dose yielding 10 % sur-
vival (D10), indicating a moderate radiosensitization
in both cell lines. The dual PI3K/mTOR inhibitor
NVP-BEZ235 sensitized both cell lines to a greaterFig. 4 Colony forming abilities of SNB19 and A549 cancer cells as function
AZD6244- (filled squares), NVP-BEZ235- (filled triangles) and AZD6244 + NVP
graded doses up to 8 Gy. Two weeks after IR colonies were fixed and stain
and repeated at least four times. Colonies containing at least 50 cells wereextent, as confirmed by a steeper decline of the sur-
vival curve and higher inhibitory factors for SF2 and
D10. In both cell lines combined incubation with
both inhibitors did not increase radiosensitization
compared to inhibition of the PI3K/mTOR signaling
cascade with NVP-BEZ235 solely.s of drug and IR exposure. Control (DMSO-treated, empty circles),
-BEZ235-treated cells (filled diamonds) were irradiated with single
ed using standard protocols. Experiments were performed in triplicates
scored as survivors
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and IR
To further explore the phenotypic changes after incubation
with AZD6244 and NVP-BEZ235 in SNB19 and A549 cells,
we analyzed the cell cycle phase distribution after MEK and
PI3K/mTOR inhibition in irradiated and sham-irradiated
cells. The summarized data of at least three independent
experiments are presented in Fig. 5, whereas representative
histograms are presented in Additional file 3. The large
percentage of SNB19 and A549 cells in the S and G2/M-
phase of the cell cycle indicates, that the cells were in the
exponential growth phase at the beginning of the experi-
ments, although cell line specific differences occurred. In-
cubation for 16 h with AZD6244 prior to IR resulted in a
slight elevation of cells in the G1-phase 30 min after IR in
both cell lines, whereas neither NVP-BEZ235 nor IR with
8 Gy had an effect on the cell cycle phase distribution at
this time point.
As confirmed by the increased fractions of G1-phase
cells 24 and 48 h after IR, both inhibitors had an anti-
proliferative effect, although an incubation of A549
cells with NVP-BEZ235 resulted in a higher proportion
of G1-phase cells than incubation of SNB19 cells. How-
ever, the combination of AZD6244 and NVP-BEZ235
synergistically increased the fraction of SNB19 cells,
whereas no additional effect were observed in A549
cells, as shown in Fig. 5 and Additional file 3. IR
resulted in cell line-specific alterations of the cell cycle,
namely in SNB19 cells IR with 8 Gy caused an elevated
proportion of G2/M-phase cells, whereas IR of A549
cells resulted in an increase of the G1-phase proportion
mainly.
The treatment with AZD6244 prior to IR caused a
moderate increase of the G1-phase fraction in addition
to the radiation induced cell cycle aberrations in both
cell lines. In contrast, perturbation of the PI3K/mTOR
signaling cascade with NVP-BEZ235 resulted in elevated
G2/M-phase levels in both cell lines up to 48 h after IR.
The simultaneous incubation with both inhibitors
caused a slight increase of the proportion of cells in the
G1-phase (less than in cells treated with AZD6244
alone) and slightly elevated G2/M-phase levels (less than
in cells treated with NVP-BEZ235 alone), as shown in
Fig. 5 and Additional file 3.
In order to elucidate the molecular basis for the alter-
ations in the cell cycle, observed in SNB19 and A549 cells
after IR and/or treatment with the inhibitors, we analyzed
the expression of the cell cycle related proteins CDK1,
CDK4 and p-Rb. As shown in Fig. 6a, neither each inhibitor
alone nor a combination of them had an effect on the
expression levels of the tested cell cycle related proteins in
both cell lines 30 min after IR. Also the exposure to 8 Gy
had no effects on the expression levels of CDK1, CDK4 and
p-Rb at this time point.A perturbation of the MAPK pathway with AZD6244
resulted in decreased expression levels of CDK1 24 and
48 h after IR in SNB19 cells (Fig. 6b and c). This was
observed independently of IR or co-incubation with NVP-
BEZ235. The phosphorylation of Rb was also reduced in
AZD6244 treated SNB19 cells, although a co-incubation
with NVP-BEZ235 resulted in a higher reduction than
treatment with AZD6244 solely. This synergistic effect of
AZD6244 and NVP-BEZ235 correlated with the enhanced
G1-phase arrest in SNB19 cells after combined incubation
with both inhibitors, as shown in Fig. 5. IR of SNB19 cells
had only minor effects on the expression levels of CDK1
and CDK4, whereas an increase of p-Rb was detected 24 h
after IR. Again in accordance to the cell cycle phase distri-
bution data, treating SNB19 cells with AZD6244 and IR
resulted in decreased levels of the G1/S-phase transition
regulator p-Rb.
The A549 cells revealed a different expression pattern of
the cell cycle related proteins after IR (Fig. 6b and c). In
SNB19 cells incubation with AZD6244 caused a slight
reduction of CDK1 expression levels, whereas this was not
detected in A549 cells. However, in accordance with the
strong G1 arrest induced by NVP-BEZ235 in A549 cells
(Fig. 5), the treatment with the dual PI3K/mTOR inhibitor
caused a slight decrease of CDK1 and CDK4 expression in
A549 cells independent of IR. The phosphorylation level
of Rb was slightly reduced by AZD6244 and to a much
greater extent by NVP-BEZ235. Simultaneous incubation
with both inhibitors only had minor further effects on the
p-Rb level in A549 cells, which is in agreement with the
cell cycle phase distribution data (as shown in Fig. 5 and
Additional file 3). An exposure of the A549 cell line to IR
also resulted in a decreased phosphorylation of Rb. This
decreased p-Rb levels were further reduced when the
A549 cells where incubated with AZD6244. Interestingly
the treatment with NVP-BEZ235 further decreased the
phosphorylation level of Rb in irradiated A549 cells. As
already observed in sham-irradiated A549 cells, also in
irradiated A549 cells the NVP-BEZ235 induced reduction
of p-Rb was not altered by simultaneous incubation with
AZD6244.
Apoptosis and autophagy induction by AZD6244, NVP-
BEZ235 and IR
To further elucidate the phenotypic effects of AZD6244
and NVP-BEZ235 in SNB19 and A549 cells, we assessed
apoptosis and autophagy induction after incubation with
the inhibitors in sham-irradiated and irradiated cells.
Figure 7a and b illustrate the mean percentage of cells
with hypodiploid DNA content and cellular debris, a
marker for late stage apoptosis, summarized from at
least three independent experiments. Representative
Western blot experiments for the expression of the
DNA repair enzyme PARP and its cleavage, as well as
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(See figure on previous page.)
Fig. 5 Effects of AZD6244, NVP-BEZ235 and IR on cell cycle phase distributions. Cell cycle phase distribution of SNB19 and A549 tumor cells treated with
AZD6244 and/or NVP-BEZ235 before IR with 8 Gy. The cells were fixed 30 min, 24 or 48 h after IR, permeabilized, treated with RNase, stained with PI and
analyzed for DNA content by flow cytometry. Data are presented as means (±SD) of G1- (light grey), S- (white) and G2/M-phase (dark grey) cells of at least
three independent experiments for each cell line. Statistical significant changes assessed as specified in the Methods section are indicated by # P< 0.05
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sented in Fig. 7c. As shown in Fig. 7a, incubation with
each inhibitor alone or in combination did not affect
the percentage of hypodiploid cells in sham-irradiated
SNB19 cells. In contrast, exposing SNB19 cells to 8 Gy
caused an increase of hypodiploid cells, which was not
enhanced by any of the two inhibitors or their combin-
ation. The data for the hypodiploid DNA content in
SNB19 cells 24 and 48 h after IR correlated with the
cleavage of PARP, as illustrated in Fig. 7c. The incubation
with AZD6244 and/or NVP-BEZ235 did not result in any
changes of PARP expression or its cleavage 24 h after IR.
However, 48 h after IR a slight increase in cleaved PARP
was observed in cells treated with both inhibitors simultan-
eously, indicating a synergistic cytotoxic effect. In addition,
we observed the cleavage of PARP when cells were exposed
to 8 Gy, which reflects the enlarged fraction of hypodiploid
cells after IR on the protein level.
In contrast to the SNB19 cell line, A549 cells showed
significant changes in the hypodiploid fraction after treat-
ment with AZD6244 and NVP-BEZ235. NVP-BEZ235
induced the reduction of the hypodiploid fraction 24 h
after IR in A549 cells (Fig. 7b). Furthermore, 48 h after IR
an increased proportion of hypodiploid cells was detected
after incubation with AZD6244. This increase was fur-
ther enhanced, when A549 cells were treated with both
inhibitors simultaneously. The elevated proportion of
hypodiploid cells in AZD6244 treated samples was also
observed in irradiated A549 cells. The incubation with
NVP-BEZ235 also resulted in a significantly increased
proportion of irradiated A549 cells with hypodiploid
DNA content. Most strikingly and as already observed
for unirradiated samples, the combination of both in-
hibitors caused the highest fraction of hypodiploid
A549 cells 48 h after IR in irradiated cells.
The simultaneous incubation with both inhibitors caused
the highest levels of cleaved PARP in unirradiated and
irradiated A549 cells 24 h after IR pointing to the induction
of apoptosis. Interestingly, 48 h after IR elevated cleaved
PARP levels were detected in A549 cells treated with
AZD6244, NVP-BEZ235 and a combination of both inhibi-
tors, whereas an elevated proportion of hypodiploid cells
was not observed for NVP-BEZ235 treated cells. However,
as shown in the flow cytometric data, the combination of
both inhibitors resulted in strongest effects in unirradiated
A549 cells. Interestingly, in irradiated A549 cells treatment
with NVP-BEZ235 alone caused a higher level of PARP
cleavage then incubation with both inhibitors 48 h after IR.To assess the impact of AZD6244, NVP-BEZ235 and IR
on the induction of autophagy, we probed for the autoph-
agy marker protein LC3, which is converted from the
cytosolic soluble LC3-I to the membrane-bound LC3-II
form during the autophagic process. As shown in Fig. 7c,
treatment of SNB19 cells with AZD6244, NVP-BEZ235
and IR had only minor effects on the expression levels of
LC3-I and LC3-II. However, in A549 cells the depletion of
LC3-I was observed 24 after IR, when the cells were
treated with the dual PI3K/mTOR inhibitor. This effect
also persisted 48 h after IR and was independent of IR or
incubation with AZD6244.
Discussion
Oncogenic signaling cascades have been identified as
potential molecular targets for the treatment of different
tumor entities [2, 11, 12, 18, 28, 36, 61]. However, depend-
ing on the mutational background of the cancer cell the
inhibition of pathways can induce the activation of com-
plementary signaling cascades [31, 34, 35, 42]. A strategy
to circumvent these cross activations is the simultaneous
inhibition of the other complementary signaling cascades.
Especially the simultaneous inhibition of the MAPK and
the PI3K/mTOR pathways, which are mutated in a multi-
plicity of human cancers, yielded promising results in vari-
ous in vitro and in vivo studies [3, 14, 23, 46, 54, 64], since
these signaling cascades are known to influence prolifera-
tion, cell growth, survival and resistance to chemothera-
peutics and IR [13, 50, 60].
Although, there is evidence that simultaneous treatment
with the MEK inhibitor AZD6244 and the PI3K/mTOR
inhibitor NVP-BEZ235 causes synergistic effects on tumor
cell proliferation and induction of apoptosis [24, 26, 53,
56, 59], little is known about the radiation response of
tumor cells after simultaneous inhibition of the MAPK
and the PI3K/mTOR pathways. Therefore, this study was
designed to integrate the network signaling and pheno-
typic data of the radiation response after simultaneous
MEK and PI3K/mTOR inhibition in SNB19 and A549
cells, which differ in their mutational status of the MAPK
and PI3K/mTOR signaling cascade [30].
As shown in Fig. 1, incubation with AZD6244 or NVP-
BEZ235 alone resulted in a dose dependent reduction of
the proliferation in SNB19 and A549, although effects of
NVP-BEZ235 were of greater magnitude in A549 cells.
Since there are no known mutations in the PI3K/mTOR
signaling cascade in A549 cells [30], it is likely, that the
different tumor entity is the main reason for the different
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Fig. 6 Effects of AZD6244, NVP-BEZ235 and IR on the induction of apoptosis and autophagy. Mean percentage of cells with hypodiploid DNA content
and cellular debris in cells treated with AZD6244 (red striped columns), NVP-BEZ235 (blue columns) or a combination of both inhibitors (red and blue
striped columns) 24 and 48 h after IR. DMSO treated cells (blank columns) served as controls. Cells were detached with trypsin, fixed, permeabilized,
treated with RNase, stained with PI and then analyzed for fluorescence by flow cytometry. The columns display means (±SD) of hypodiploid cells and
cellular debris of at least three independent experiments. Statistical significant differences are indicated as follows: # P < 0.05; ## P <0.01. Statistical
significant differences between sham-irradiated and irradiated control samples are not depicted for reasons of clarity. Representative Western blot
analysis of expression levels of PARP, cleaved PARP, LC3-I and LC3-II in SNB19 and A549 cells c. Cells were treated with AZD6244 and/or NVP-BEZ235
before IR with 8 Gy and whole cell lysates were prepared 24 and 48 h after IR as described previously. Protein bands were normalized to the
β-actin intensity and changes in protein expression are denoted by numbers if applicable. The experiment was repeated at least three times
Kuger et al. Radiation Oncology  (2015) 10:214 Page 11 of 16
B)
A)
C)
Fig. 7 Effects of AZD6244, NVP-BEZ235 and IR on cell cycle related proteins. Representative Western blot analysis of expression levels of selected
proteins associated with the cell cycle in SNB19 and A549 cells. Cells were treated with AZD6244 and/or NVP-BEZ235 before IR with 8 Gy and whole
cell lysates were prepared 30 min a, 24 b and 48 h c after IR as described previously. Protein bands were normalized to the β-actin intensity and
changes in protein expression are denoted by numbers if applicable. The experiment was repeated at least three times
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ing NVP-BEZ235 with AZD6244 basically resulted in the
same proliferation rates as incubation with NVP-BEZ235,
implicating that NVP-BEZ235 is the more effective
inhibitor.
To elucidate possible reasons for the observed anti-
proliferative effects, we analyzed the expression levels of
certain key players of the MAPK and PI3K/mTOR signal-
ing cascades after pathway perturbation with AZD6244
and NVP-BEZ235. As expected and in accordance with
published results for different tumor entities, the treat-
ment with AZD6244 and NVP-BEZ235 alone resulted in
inhibition of the MAPK and PI3K/mTOR signaling
cascade, respectively, as confirmed by reduced expression
of p-Erk, p-Akt, p-S6 and p-4E-BP1 (Fig. 2). However, we
also observed the induction of feedback loops by the two
inhibitors, indicated by elevated levels of MEK1/2 (after
MEK inhibition) and Akt phosphorylation (after PI3K/
mTOR inhibition) after prolonged incubation with the
inhibitors, which has already been reported for NVP-
BEZ235 in other glioblastoma cell lines [38, 41, 44]. Note-
worthy, extended incubation with NVP-BEZ235 also re-
sulted in reduced Raf-1 expression in both cell lines
(Fig. 2a), indicating a crosstalk between the two signaling
cascades, as depicted in our putative signaling diagram
(Fig. 3) and as already published for other cell lines [3, 23, 46].
Apart from the effects on proliferation and the signaling
cascades we also assessed the clonogenic ability of SNB19
and A549 cells after IR and incubation with the inhibitors
(Fig. 4). In both cell lines AZD6244 caused a radiosensiti-
zation, as reported in other studies [9, 10, 62], although
only to a moderate extent. A treatment with NVP-BEZ235
resulted in a more profound radiosensitization in both cell
lines, indicating that NVP-BEZ235 is the drug which
yielded the greater cytotoxic effects, when combined with
IR. The NVP-BEZ235 mediated radiosensitization also is
in accordance with published data [20, 21, 51, 73]. How-
ever, the fact, that in both cell lines combining AZD6244
and NVP-BEZ235 yielded the same result as the dual
PI3K/mTOR inhibitor alone, implies that no synergistic or
additive effects occurred in SNB19 and A549 cells in
terms of radiosensitivity. This is in contrast to previous
published results of combining MAPK and PI3K/mTOR
pathway inhibitors using a MEK and an Akt inhibitor in
pancreatic cancer cells [67], which again confirms that the
results of pathway perturbations highly rely on the inhibi-
tors and the genetic background of the treated cells.
To further assess the phenotypic effects in the two
tested cell lines after signaling cascade inhibition, we ana-
lyzed the cell cycle phase distributions. The incubation
with AZD6244 or NVP-BEZ235 caused cell cycle arrests
in the G1-phase in both cell lines, as shown in Fig. 5 and
Additional file 3. The combination of both inhibitors
resulted in an even more profound arrest in the G1-phasein SNB19 cells, whereas no additive or synergistic effects
were observed in A549 cells, which is most likely due to
the extensive cytostatic effect of NVP-BEZ235 in this cell
line. Our Western blot data of the cell cycle related pro-
teins further confirm the flow cytometric data (compare
Fig. 6). A treatment with both inhibitors simultaneously
resulted in greatest reduction of p-Rb in SNB19 cells,
which is an indicator for a blockade at the G1/S-transition
checkpoint [33, 45, 65], whereas in A549 cells treatment
with NVP-BEZ235 alone already reduced p-Rb expression
levels to a maximum. This enhanced cell cycle arrest in
the SNB19 cell line after combined MEK and PI3K/
mTOR inhibition, indicates an additive or synergistic
anti-proliferative effect of AZD6244 and NVP-BEZ235,
which has not been shown for glioblastoma cell lines
yet, indicating a therapeutically relevant potential of
combining these two inhibitors in this tumor entity.
Combining IR and AZD6244 increased the propor-
tion of G1-phase cells in both cell lines, whereas the
combination of NVP-BEZ235 and IR resulted in ele-
vated levels of G2/M-phase cells, as shown previously
for other cell lines [37, 38]. A simultaneous inhibition
of the MAPK and the PI3K/mTOR signaling cascades
in irradiated cells resulted in mixed phenotypic effects
as observed for the combination of IR with each inhibi-
tor alone. Apparently the two inhibitors are somewhat
counteracting each other, which might be a reason for
the lack of synergy in terms of radiosensitization.
To further elucidate the effects of MEK and PI3K/mTOR
inhibition, we assessed the induction of apoptosis and au-
tophagy. As shown in Fig. 7, incubation with AZD6244 had
no relevant effects on apoptosis and autophagy in SNB19
cells, whereas treatment with NVP-BEZ235 caused a slight
induction of autophagy 24 h after IR. Combining both
inhibitors increased cleaved PARP levels slightly, indicating
apoptosis and validating a synergistic effect of the two
drugs 48 h after IR in the glioblastoma cell line. However,
IR of SNB19 cells increased the hypodiploid fraction and
the expression level of cleaved PARP to a greater ex-
tent. Most strikingly, this radiation induced apoptosis
was slightly enhanced, when irradiated cells were
treated with both inhibitors simultaneously.
This is in contrast to the A549 cell line, indicating a cell
line specific effect: Although the highest levels of cleaved
PARP in unirradiated cells were observed, when cells were
treated with both inhibitors, this was not true for irradi-
ated A549 cells. When A549 cells were irradiated interest-
ingly the highest rate of cleaved PARP was detected in
cells treated with NVP-BEZ235 solely. Simultaneous treat-
ment of irradiated cells with AZD6244 and NVP-BEZ235
resulted in lower levels of cleaved PARP (Fig. 7), indicating
less induction of apoptosis.
Another difference between the cell lines in their re-
sponse to AZD6244 and NVP-BEZ235 was observed in
Kuger et al. Radiation Oncology  (2015) 10:214 Page 14 of 16autophagy. When SNB19 cells were treated with NVP-
BEZ235 only a slight induction of autophagy was observed
24 h after IR, as validated by a slight increase of LC3-II.
However, A549 cells revealed a complete depletion of
LC3-I but no increase of LC3-II. This can be due to
the fact, that within the autophagic process the initially
increased LC3-II levels are degraded within a few hours
after induction of autophagy [48]. This might indicate
that the autophagic process is much faster in the lung
carcinoma cell line. The induction of autophagy by
NVP-BEZ235 was already reported for breast cancer
cells lines and is of utmost interest [37], since the role
of autophagy in cancer is currently highly discussed
[29, 39, 57]. Furthermore, several research groups
demonstrated, that inhibitors of the autophagic flux,
such as bafilomycin A or chloroquine, can sensitize
cancer cells to IR [4, 72]. Therefore, this NVP-BEZ235-
mediated induction of autophagy might be exploited to
further enhance the radiosensitization with autophagy
inhibitors.
Conclusions
In this study we clearly demonstrated, that our novel
approach of combining AZD6244 and NVP-BEZ235
with IR resulted in pathway perturbations and cell line
specific effects. In SNB19 cells mainly synergistic cyto-
static effects were observed after simultaneous treat-
ment with AZD6244 and NVP-BEZ235, whereas the
combination of the same drugs induced apoptosis to a
much greater extent in A549 cells. However, apart from
the synergistic effects in unirradiated cells, our study
also clearly shows, that there are no additive effects in
terms of radiosensitivity, when the two radiosensitizers
are used in combination.
One major question, which arises from the data pre-
sented in this study, is, if the different effects of the com-
bined treatment with AZD6244 and NVP-BEZ235 in the
glioblastoma SNB19 and lung carcinoma A549 cells rely
on the different mutational background (SNB19 cells are
TP53 and PTEN mutated, whereas A549 cells are KRAS
mutated) or on the different tumor entity. A systematic
approach addressing this question will be the subject of
forthcoming in vitro and in vivo experiments, improving
our knowledge about how specific mutations and the can-
cer cell origin affect the impact of inhibiting the MAPK
and the PI3K/mTOR pathways. The data generated in
these forthcoming experiments will help to improve our
putative signaling network, which we presented in this
study, ultimately facilitating valid predictions of how the
effects of an inhibitor depend on certain mutations and/or
the tumor cell origin. This will pave the way for a person-
alized therapy regimen, which is based on the genetic
background of an individual cancer, in order to enhance
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